Zydus Lifesciences (ZYDUSLIFE) | Stock Overview & Key Data
Zydus Lifesciences Performance Comparison
Stock Range
Today's Range
Low: ₹980.45
High: ₹997.90
on September 30, 2025
52 Week Range
Low: ₹795.00
High: ₹1,088.85
on April 7, 2025
on September 30, 2024
All-Time High: ₹1,324.30 on August 5, 2024
Explore how other Indian stocks compare to their 52-week ranges: View IN Market 52-Week Insights
Key Statistics
Market Cap
INR998.4B
EPS
45.44
P/E Ratio (TTM)
21.81
Forward P/E
24.11
P/B Ratio
4.16
PEG Ratio
6.55
Div. Yield
1.44%
ROE
17.17%
Beta
0.468
Debt to Equity
12.21
Financial Highlights
Profitability
Gross Margin
72.33%
Operating Margin
27.28%
Profit Margin
19.37%
Returns and Earnings
Return on Assets (TTM)
12.16%
Return on Equity (TTM)
17.17%
EBITDA
INR72.1B
Net Income (TTM)
INR45.7B
Growth
Revenue (TTM)
Revenue Per Share (TTM)
INR234.61
Quarterly Revenue Growth (YoY)
5.90%
Quarterly Earnings Growth (YoY)
3.30%
Dividend Information
Last 12-Month Dividend
₹14.00
Current Dividend Yield
1.44%
3-Year Average Dividend Yield
0.79%
3-Year Average Annual Dividend
₹9.50
3-Year Total Dividends
₹28.50
Ex-Dividend Date
July 25, 2025
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Zydus Lifesciences ZYDUSLIFE | 998.40B Large-cap | -6.02% | -0.92% | -0.81% | 11.90% | 0.83% | -7.14% | 132.68% | 124.18% |
| Sun Pharmaceutical SUNPHARMA | 3.92T Large-cap | 2.80% | 3.33% | -2.89% | -7.84% | -13.69% | -14.60% | 70.78% | 218.03% |
| Divi's Laboratories DIVISLAB | 1.61T Large-cap | 3.10% | -4.83% | -14.69% | 1.79% | -3.41% | 8.12% | 57.02% | 83.89% |
| Torrent TORNTPHARM | 1.24T Large-cap | -1.30% | -2.55% | 5.42% | 8.22% | 2.81% | 1.18% | 123.52% | 25.54% |
| Cipla CIPLA | 1.22T Large-cap | 1.22% | -3.85% | 0.60% | 1.47% | 2.59% | 5.43% | 34.25% | 88.97% |
| Dr. Reddy's DRREDDY | 1.05T Large-cap | -0.40% | -1.12% | -3.35% | 8.39% | -8.83% | -5.92% | 42.59% | 21.10% |
Ownership & Short Interest
Insider Ownership
75.16%
Institutional Ownership
14.21%
Shares Short
N/A
Short Ratio
N/A
Short % of Shares Outstanding
N/A
Average 10-Day Volume
1M
Average 90-Day Volume
1M
Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is ZYDUSLIFE's 52-week high and low?
- In the last 52 weeks, Zydus Lifesciences reached a high of ₹1,088.85 (on September 30, 2024) and a low of ₹795.00 (on April 7, 2025).
- What is the market cap and P/E ratio for ZYDUSLIFE?
- Curious about Zydus Lifesciences's size and valuation? Its market capitalization stands at 998.40B. When it comes to valuation, the P/E ratio (trailing twelve months) is 21.81, and the forward P/E (looking ahead) is 24.11.
- Does ZYDUSLIFE pay dividends? If so, what's the yield?
- Yes, Zydus Lifesciences is a dividend-paying stock. Investors have recently enjoyed a trailing annual dividend yield of 1.44%, and the company has paid an average of ₹9.50 per share annually over the past 3 years.
- Who are Zydus Lifesciences's main competitors or similar companies to consider before investing?
When looking at Zydus Lifesciences, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Sun Pharmaceutical
SUNPHARMA3.92T Healthcare Drug Manufacturers - Specialty & Generic -14.60% 70.78% Divi's Laboratories
DIVISLAB1.61T Healthcare Drug Manufacturers - Specialty & Generic 8.12% 57.02% Torrent
TORNTPHARM1.24T Healthcare Drug Manufacturers - Specialty & Generic 1.18% 123.52% Cipla
CIPLA1.22T Healthcare Drug Manufacturers - Specialty & Generic 5.43% 34.25% Dr. Reddy's
DRREDDY1.05T Healthcare Drug Manufacturers - Specialty & Generic -5.92% 42.59% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Zydus Lifesciences Ltd.? (e.g., ROE, Debt/Equity)
- To get a sense of Zydus Lifesciences's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 17.17%, the Debt to Equity ratio from the most recent quarter is 12.21, and its Gross Profit Margin stands at 72.33%.
- What is the recent revenue and earnings growth for ZYDUSLIFE?
- Looking at Zydus Lifesciences's growth, its revenue over the trailing twelve months (TTM) was INR236B. Compared to the same quarter last year (YoY), quarterly revenue grew by 5.90%, and quarterly earnings saw a YoY growth of 3.30%.
- How much of ZYDUSLIFE stock is held by insiders and institutions?
- Wondering who owns Zydus Lifesciences stock? Company insiders (like executives and directors) hold about 75.16% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 14.21%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.